Medtronic (MDT) has drawn fresh attention after recent trading left the stock down about 13% over the past month and about 23% over the past 3 months, prompting investors to reassess its long term profile.

At a share price of $76.15, Medtronic’s short term momentum has clearly softened, with the share price falling 12.6% over the past month and 23.5% over the past quarter, while the 1 year total shareholder return is down 9.1%. This points to fading sentiment despite dividends.

If this pullback has you rethinking healthcare exposure, it can help to widen the lens with other medical technology ideas, including companies using AI in care delivery via our screener for 32 healthcare AI stocks

With Medtronic trading at $76.15 and reference points like analyst targets and intrinsic value estimates suggesting a discount, the real question is whether investors are seeing a genuine opportunity or if the stock already reflects future growth.

Most Popular Narrative: 19.8% Undervalued

According to the most followed narrative, Medtronic’s fair value sits at $95, compared with the recent share price of $76.15, which frames the current pullback as a sizable discount.

Medtronic operates across four key segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. This structure provides revenue stability and reduces dependency on any single product line. This diversification surpasses more specialized competitors like Boston Scientific or Intuitive Surgical, which are more concentrated in specific therapy areas.

Want to see what supports that gap between fair value and price? The narrative leans heavily on cash generation, steady revenue expansion, and margins that assume a premium medtech profile. Curious which segment mix and long term profitability assumptions sit under that $95 figure? The full narrative breaks down the numbers in detail.

Result: Fair Value of $95 (UNDERVALUED)

However, this story can break if regulatory setbacks or product recalls resurface, or if the Diabetes segment’s execution continues to lag stronger competitors in glucose monitoring.

Next Steps

The pullback and valuation gap raise questions, so it makes sense to review the underlying data yourself and decide quickly where you stand. To understand why some investors still see upside potential, review the 6 key rewards.

Looking for more investment ideas?

If this update has sharpened your view on Medtronic, do not stop here. Broaden your watchlist with other stocks that might suit your style and risk tolerance.

• Target potential bargains by scanning companies that look mispriced on quality and value using the 50 high quality undervalued stocks.
• Strengthen your income focus by checking out stocks that offer robust yields and payout histories through the 12 dividend fortresses.
• Prioritise resilience by reviewing companies with cleaner balance sheets and solid fundamentals via the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.